Bortezomib

Generic Name
Bortezomib
Brand Names
Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
Drug Type
Small Molecule
Chemical Formula
C19H25BN4O4
CAS Number
179324-69-7
Unique Ingredient Identifier
69G8BD63PP
Background

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication

Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions
Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Associated Therapies
-
Clinical Trials
Related News

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

First Posted Date
2012-02-13
Last Posted Date
2015-06-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
14
Registration Number
NCT01531998
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bortezomib Consolidation Trial

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Bortezomib
First Posted Date
2012-01-25
Last Posted Date
2019-04-17
Lead Sponsor
University College, London
Target Recruit Count
40
Registration Number
NCT01517724
Locations
🇬🇧

University College London, London, United Kingdom

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

Phase 1
Completed
Conditions
Mantle Cell Lymphoma
Interventions
Drug: Panobinostat
Drug: Bortezomib
First Posted Date
2012-01-05
Last Posted Date
2014-09-19
Lead Sponsor
Anand Jillella
Target Recruit Count
3
Registration Number
NCT01504776
Locations
🇺🇸

Georgia Regents University, Augusta, Georgia, United States

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

First Posted Date
2011-12-22
Last Posted Date
2020-04-07
Lead Sponsor
Celgene
Target Recruit Count
34
Registration Number
NCT01497093
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 3 locations

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

First Posted Date
2011-12-15
Last Posted Date
2012-05-11
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Registration Number
NCT01492881
Locations
🇺🇸

Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

First Posted Date
2011-12-06
Last Posted Date
2015-10-12
Lead Sponsor
Emory University
Target Recruit Count
8
Registration Number
NCT01485835
Locations
🇺🇸

The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States

🇺🇸

Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

🇺🇸

Levine Cancer Institute, Charlotte, North Carolina, United States

and more 5 locations

ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

First Posted Date
2011-11-29
Last Posted Date
2019-03-01
Lead Sponsor
Vejle Hospital
Target Recruit Count
35
Registration Number
NCT01481194
Locations
🇩🇰

Department of Hematology, Vejle, Denmark

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

First Posted Date
2011-11-23
Last Posted Date
2018-05-21
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
185
Registration Number
NCT01478048
Locations
🇺🇸

Cancer Center Of Acadiana, Lafayette, Louisiana, United States

🇺🇸

Medical University Of South Carolina, Charleston, South Carolina, United States

🇺🇸

Ucla Department Of Medicine, Los Angeles, California, United States

and more 28 locations

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

First Posted Date
2011-11-11
Last Posted Date
2018-12-19
Lead Sponsor
AB Science
Target Recruit Count
147
Registration Number
NCT01470131
Locations
🇺🇸

Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States

🇫🇷

CHU Estaing, Clermont Ferrand, France

🇫🇷

CH Le Mans, Le Mans, France

and more 10 locations

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

First Posted Date
2011-11-04
Last Posted Date
2017-04-04
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
6
Registration Number
NCT01465386
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy